Home/Pipeline/Breyanzi (lisocabtagene)

Breyanzi (lisocabtagene)

B-cell lymphomas

CommercialApproved

Key Facts

Indication

B-cell lymphomas

Phase

Commercial

Status

Approved

Company

Bristol Myers Squibb

About Bristol Myers Squibb

Bristol Myers Squibb operates as a premier global biopharmaceutical company with a mission to transform patients' lives through science. The company maintains leadership positions in oncology, hematology, cardiovascular, and immunology therapeutic areas with blockbuster products and innovative treatment modalities. BMS employs a research strategy rooted in causal human biology and diverse platform technologies to deliver first- and best-in-class medicines to patients worldwide.

View full company profile

Therapeutic Areas

Oncology Hematology Cardiovascular Immunology Neuroscience

Other B-cell lymphomas Drugs

Drug	Company	Phase	Status
Rituximab Biosimilar	Hansoh Pharma	Approved	Marketed